

R H I N O M E D

ANNUAL GENERAL MEETING
NOVEMBER 8th 2016 - MELBOURNE

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects. Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

WHO IS RHINOMED

GLOBALLY EXPERIENCED BOARD OF DIRECTORS

Mr Ron Dewhurst - Chairman	Previously Head of Americas JP Morgan, EVP Head of Global Investment Managers Legg Mason Inc, MD of IOOF Holdings Ltd, CEO ANZ McCaughan Ltd. Currently Director of OneVue Ltd
-----------------------------------	--

Mr Michael Johnson - CEO and Managing Director	CEO since February 2013
---	-------------------------

Mr Brent Scrimshaw - Non Exec Director	Previously VP & CEO Nike Western Europe, VP & CMO Nike Europe, Middle East & Africa, GM Nike USA (East), CMO Nike Australia and NZ. Currently Non Exec Director Catapult Ltd (ASX: CAT) and CEO Unscript'd Pty Ltd
---	--

Dr Eric Knight - Non Exec Director	Previously Lawyer Baker McKenzie, Consultant Boston Consulting Group. Currently University Sydney Business School, member Commonwealth Administrative Appeals Tribunal
---	--

ASX: RNO

Market Cap ~ AU\$ 14 million	Shares on Issue: 816m
-------------------------------------	-----------------------

Offices: Melbourne, Australia and Cincinnati, USA	Staff: 11
--	-----------


Top Five Shareholders	<ol style="list-style-type: none">1. Kroy Wen - 8.67%2. Merrill Lynch (Aust) Nominees - 6.00%3. HSBC Custody Nominees - 3.30%4. Abingdon Nominees - 2.56%5. Fifty Second Celebration Pty Ltd - 1.73%
------------------------------	--

ONE IN FOUR PEOPLE¹ WILL HAVE
A PROBLEM BREATHING THROUGH
THEIR NOSE.


WE HAVE CREATED AN ELEGANTLY
DESIGNED AND PATENTED PLATFORM
THAT SOLVES THIS PROBLEM IN
MULTIPLE SITUATIONS.

| DURING EXERCISE | AT NIGHT | WHEN ILL | WHEN ASLEEP |


A NOVEL NASAL TECHNOLOGY PLATFORM



THE TECHNOLOGY PLATFORM



ESTABLISHED GLOBAL PRODUCTION AND LOGISTICS NETWORK



- Provides global logistics support from its Hong Kong hub
- Fulfillment to key US and European Distribution warehouses
- Provides direct to consumer fulfillment services



- Situated in Jiaotang, Gaoyao, Zhaoqing in Guangdong
- Certified ISO13485-2003 and QSR820 facility
- RNO has 5 dedicated tooling, production, assembly and packaging lines - production capacity of 3.9 million pack pa.



- Provides UK warehousing, customs and logistics support
- Distribution into Boots warehouses
- Provides direct to consumer fulfillment services for UK, IE and EU.

TURBINE - HELPING ATHLETES TO BREATHE BETTER



- Designed to help athletes breathe easier during sport and aerobic exercise and help those suffering from nasal obstruction
- Now distributed globally - exclusively through Vittoria industries in the US
- Athletes wearing Turbine won the Tour de France, GOLD and bronze at the RIO Olympics, came 4th in the women's 1500m and 6th in the Men's marathon

MUTE - CLINICALLY BACKED INNOVATION



- A comfortable, scientifically proven, disposable nasal stent that improves airflow and reduces snoring
- Adjustable for each nostril to ensure ultimate comfort and fit
- Each pack contains 3 Mutes
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- Reusable up to 10 times, thus small, medium & large pack lasts 30 days

BUILDING A CUSTOMER BASE



CHRIS FROOME

BREATHING
ISSUES



SHANNON ROWBURY

NASAL
OBSTRUCTION




EMILY GIANNOPOULOS

PRIMARY SNORING



JENNY CHAPMAN






SEVERE SNORING




MARK PACHACZ

SLEEP APNEA

BUILDING A DISTRIBUTION CHANNEL


				
SPECIALTY RETAIL	MAINSTREAM RETAIL	ONLINE	PHARMACY & GROCERY	CLINICAL
PERFORMANCE BIKE GIANT VITTORIA INDUSTRIES	DICK'S SPORTING GOODS	AMAZON DRUGSTORE.COM 1800CPAP.COM CPAP SUPPLY USA MUTESNORING.COM THETURBINE.COM JET.COM INBOX FITNESS BOOTS.COM SLUMBER BUMP	BOOTS DUANE READE WALGREENS SYMBION SIGMA API CVS MCKESSONS PHARMACYONLINE.COM OBORNE HEALTH SUPPLIES	SLEEP CLINICS DOCTORS DENTISTS

MAIN ACHIEVEMENTS – DISTRIBUTION



STRONG STORE NUMBER GROWTH IN KEY MARKETS

STORE NUMBERS (GLOBAL)



- Global roll out all within 15 months
- 3000+ stores live today (plus strong pipeline)
- Footprint in Australia, UK, Canada and USA

STRONG RETAIL AND WHOLESALE PARTNERS

Walgreens

DUANEreade™



drugstore.com™
the uncommon drugstore



jet



amazon



PERFORMANCE
BICYCLE



cpasupplyusa

1800CPAP.COM

We Deliver. You Sleep.


CVS
pharmacy®

MCKESSON
Empowering Healthcare

Vittoria

DELIVERED CONTINUOUS GROWTH IN SALES – 134% INCREASE IN REVENUE

REVENUE



- Strong start to FY17
- Q1 FY17 revenue up 79% to \$533k
- Burn rate down 48%
- Cash receipts up 59% to \$539k

GROWTH DRIVERS

RETAIL



- Scale in store numbers in Australia, USA, Canada and UK – Target: 13,000 FY17
- Premium in-store experience and presence – Drive sell-through
- Establish Mute technology as the entry point to the global sleep category

ONLINE




- Leading provider of content that informs and educates
- Curate an active and vibrant community and conversation

CLINICAL




- Become the preferred solution for nasal obstruction by Doctors and Dentists

THE GLOBAL SLEEP MARKET IS AWAKENING



SLEEP JOURNEY



RHINOMED IS POSITIONED TO TAKE ADVANTAGE

HYPERCOMPETITION

NO SIGNIFICANT INNOVATION

INCREASING PUBLIC AWARENESS

SIGNIFICANT PRESSURE ON COSTS

INVESTMENT PROPOSITION




MARKET

Compelling technology in a growing global market - Sleep



DISTRIBUTION

Business is rapidly expanding the revenue base through a global distribution footprint



KEY FOCUS

- USA & CANADA
- UK
- Aust/NZ Base



NEAR-TERM NEWS FLOW

- Growing number of distributors



COMPELLING INVESTMENT COMPARATOR

- Breathe Right™ Strips - Peak revenues of approximately US\$150m
- Purchased by GSK - US\$566m in 2007

MICHAEL JOHNSON, CEO
e. mjohnson@rhinomed.global
t. +61 3 8416 0900
www.rhinomed.global

© RHINOMED LTD.